Exploring the Influence of Schisandrin B on Mice with Multiple Myeloma
Anna Li1, Hongchao Sheng1, Yan Zou1
1Department of Hematology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang 330006, China.
Background/Aims:
The management of multiple myeloma (MM), a formidable hematological malignancy, continues to pose substantial challenges. Schisandrin B (Sch B), a bioactive compound derived from Traditional Chinese Medicine, has demonstrated potent antitumor properties, but its in vivo effects on MM remain unclear.
Methods:
Tumor growth was evaluated by measuring body weight, tumor volume, and cell proliferation. Cell cycle progression and apoptosis were analyzed by flow cytometry. ELISA was performed to quantify interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF). Reactive oxygen species (ROS) were detected by immunofluorescence, and Western blotting was used to determine the expression of IL-6, JAK2, phosphorylated JAK2 (p-JAK2), STAT3, and phosphorylated STAT3 (p-STAT3).
Results:
Sch B markedly inhibited tumor proliferation, induced S-phase cell cycle arrest, and promoted apoptosis. Sch B reduced the expression of IL-6, VEGF, p-JAK2, and p-STAT3 while increasing ROS levels in mice with MM. Moreover, Sch B exhibited a synergistic antitumor effect when combined with bortezomib.
Conclusion:
Schisandrin B represents a promising therapeutic candidate for multiple myeloma, and its antitumor efficacy is further enhanced in combination with bortezomib.
